Mohamed-Rachid Boulassel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamed-Rachid Boulassel has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Jean-Pierre Routy
3 shared publicationsRichard G. Lalonde
Immunodeficiency Service, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada
2 shared publications- Alexandre Iannello
University of Montréal, Montréal, QC, Canada
1 shared publication - Ali Ahmad
Ste-Justine Hospital Research Center, Montreal, QC
1 shared publication - Bernard Lessard
Clinique du Quartier Latin, Montréal, Québec, Canada
1 shared publication - Bobby M. Chauhan
Office of Science Laboratory, Therapeutics Products Program, Health Canada, 0900C2, Ottawa, K1A 0K9, Canada
1 shared publication
Latest Publications
- Open Access
- 4 September 2012
- Published by Sultan Qaboos University in Sultan Qaboos University Medical Journal
- Vol. 12 (2) , 137-139
A New Cellular Weapon to Kill Leukaemic B-Cells
By Mohamed-Rachid Boulassel, Published on 09/04/12
- 4 September 2012
- Published by Sultan Qaboos University in Sultan Qaboos University Medical Journal
- Vol. 12 (2) , 137-139
Open AccessA New Cellular Weapon to Kill Leukaemic B-Cells
By Mohamed-Rachid Boulassel, Published on 09/04/12
- Open Access
The Effect of β-Carotene Supplementation on the Pharmacokinetics of Nelfinavir and Its Active Metabolite M8 in HIV-1-infected Patients
β-Carotene supplements are often taken by individuals living with HIV-1. Contradictory results from in vitro studies suggest that β-carotene may inhibit or induce cytochrome P450 enzymes and transporters. The study objective was to investigate the effect of β-carotene on the steady-state pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1 infected individuals. Twelve hour nelfinavir pharmacokinetic analysis was conducted at baseline and after 28 days of β-carotene supplementation (25,000 IU twice daily). Nelfinavir and M8 concentrations were measured with validated assays. Non-compartmental methods were used to calculate the pharmacokinetic parameters. Geometric mean ratios comparing day 28 to day 1 area under the plasma concentration-time curve (AUC0–12 h), maximum (Cmax) and minimum (Cmin) concentrations of nelfinavir and M8 are presented with 90% confidence intervals. Eleven subjects completed the study and were included in the analysis. There were no significant differences in nelfinavir AUC0–12 h and Cmin (−10%, +4%) after β-carotene supplementation. The M8 Cmin was increased by 31% while the M8 AUC0–12 h and Cmax were unchanged. During the 28 day period, mean CD4+ % and CD4+:CD8+ ratio increased significantly (p < 0.01). β-carotene supplementation increased serum carotene levels but did not cause any clinically significant difference in the nelfinavir and M8 exposure.
Open AccessThe Effect of β-Carotene Supplementation on the Pharmacokinetics of Nelfinavir and Its Active Metabolite M8 in HIV-1-infected Patients
β-Carotene supplements are often taken by individuals living with HIV-1. Contradictory results from in vitro studies suggest that β-carotene may inhibit or induce cytochrome P450 enzymes and transporters. The study objective was to investigate the effect of β-carotene on the steady-state pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1 infected individuals. Twelve hour nelfinavir pharmacokinetic analysis was conducted at baseline and after 28 days of β-carotene supplementation (25,000 IU twice daily). Nelfinavir and M8 concentrations were measured with validated assays. Non-compartmental methods were used to calculate the pharmacokinetic parameters. Geometric mean ratios comparing day 28 to day 1 area under the plasma concentration-time curve (AUC0–12 h), maximum (Cmax) and minimum (Cmin) concentrations of nelfinavir and M8 are presented with 90% confidence intervals. Eleven subjects completed the study and were included in the analysis. There were no significant differences in nelfinavir AUC0–12 h and Cmin (−10%, +4%) after β-carotene supplementation. The M8 Cmin was increased by 31% while the M8 AUC0–12 h and Cmax were unchanged. During the 28 day period, mean CD4+ % and CD4+:CD8+ ratio increased significantly (p < 0.01). β-carotene supplementation increased serum carotene levels but did not cause any clinically significant difference in the nelfinavir and M8 exposure.
- 1 January 2012
- Published by Elsevier in Journal of Clinical Virology
- Vol. 53 (1) , 29-32
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy
- 1 January 2012
- Published by Elsevier in Journal of Clinical Virology
- Vol. 53 (1) , 29-32
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy
- Open Access
- 16 June 2011
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 8 (1) , 20
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
Elite controllers (EC) are a rare subset of HIV infected individuals who control viral load below 50 copies/ml of plasma without treatment. Thirty four EC were studied. The slope of CD4 count change was available for 25 of these subjects. We assessed immune activation by measuring the percent of CD38+HLA-DR+CD8+ T cells in the EC group and comparing it with that in 24 treatment-naïve HIV disease progressors and 13 HIV uninfected healthy controls. Compared to HIV uninfected subjects, EC had higher percentages of CD38+HLA-DR+CD8+ T cells (p < 0.001) that was lower than that observed in progressors (p < 0.01). Fifteen of 25 EC had a slope of CD4 count change that was not significantly different from 0 while 3 had a positive and 7 a negative CD4 count slope. Immune activation did not distinguish EC subsets with stable/increasing versus declining CD4 counts. Elevated immune activation in ECs is not associated with a faster rate of CD4 decline
- 16 June 2011
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 8 (1) , 20
Open AccessT cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
Elite controllers (EC) are a rare subset of HIV infected individuals who control viral load below 50 copies/ml of plasma without treatment. Thirty four EC were studied. The slope of CD4 count change was available for 25 of these subjects. We assessed immune activation by measuring the percent of CD38+HLA-DR+CD8+ T cells in the EC group and comparing it with that in 24 treatment-naïve HIV disease progressors and 13 HIV uninfected healthy controls. Compared to HIV uninfected subjects, EC had higher percentages of CD38+HLA-DR+CD8+ T cells (p < 0.001) that was lower than that observed in progressors (p < 0.01). Fifteen of 25 EC had a slope of CD4 count change that was not significantly different from 0 while 3 had a positive and 7 a negative CD4 count slope. Immune activation did not distinguish EC subsets with stable/increasing versus declining CD4 counts. Elevated immune activation in ECs is not associated with a faster rate of CD4 decline
- 31 December 2010
- Published by Elsevier in Clinical Immunology
- Vol. 135, S108
Association Between IL-21 Serum Concentrations, CD4+ T Cells Survival as well as CD8+ T Cells Frequency and Polyfunctionality in HIV-infected Patients
- 31 December 2010
- Published by Elsevier in Clinical Immunology
- Vol. 135, S108
Association Between IL-21 Serum Concentrations, CD4+ T Cells Survival as well as CD8+ T Cells Frequency and Polyfunctionality in HIV-infected Patients
- 1 March 2008
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 8 (1) , 59-60
Clinical significance of autoantibodies to inner ear antigens in sera of patients with systemic diseases
- 1 March 2008
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 8 (1) , 59-60
Clinical significance of autoantibodies to inner ear antigens in sera of patients with systemic diseases
- 1 September 2006
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (9) , 1158-1163
Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons
Gender differences in a large population‐based cohort of HIV‐1 infected patients (245 women and 723 men) were examined with respect to the incidence of metabolic and morphologic alterations after initiation of highly active antiretroviral therapy (HAART). Patients initiated HAART between January 1996 and December 2003. The outcome measures were the incidence of hyperglycemia, hypercholesterolemia, symptomatic lactic acidosis, treatment‐limiting lipodystrophy, and hypersensitivity reaction. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios of reaching the endpoints for exposures and covariates. Women were younger than men (35 ± 9.8 vs. 40 ± 8.2 years, P < 0.001) and more frequently from Haiti or Africa (59%), whereas 76% of men were Canadian‐born. Type of initial HAART regimen did not differ between women and men. There were no gender differences in the overall incidence of hyperglycemia, hypercholesterolemia, or treatment‐limiting lipodystrophy, even after adjusting for age, CD4 cell count, viral load, time since HIV diagnosis, history of AIDS‐defining illness and year of HAART initiation. In contrast, women had significantly higher risk of developing lactic acidosis than men (P = 0.0009). Hypersensitivity reactions were also more frequent in women than men (adjusted hazard ratio = 4.4 (95% CI: 2.1–9.3)). Collectively, these data suggest that metabolic toxicities after HAART do not differ by gender but that lactic acidosis and hypersensitivity reactions are more frequent in women than men. J. Med. Virol. 78:1158–1163, 2006.
- 1 September 2006
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (9) , 1158-1163
Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons
Gender differences in a large population‐based cohort of HIV‐1 infected patients (245 women and 723 men) were examined with respect to the incidence of metabolic and morphologic alterations after initiation of highly active antiretroviral therapy (HAART). Patients initiated HAART between January 1996 and December 2003. The outcome measures were the incidence of hyperglycemia, hypercholesterolemia, symptomatic lactic acidosis, treatment‐limiting lipodystrophy, and hypersensitivity reaction. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios of reaching the endpoints for exposures and covariates. Women were younger than men (35 ± 9.8 vs. 40 ± 8.2 years, P < 0.001) and more frequently from Haiti or Africa (59%), whereas 76% of men were Canadian‐born. Type of initial HAART regimen did not differ between women and men. There were no gender differences in the overall incidence of hyperglycemia, hypercholesterolemia, or treatment‐limiting lipodystrophy, even after adjusting for age, CD4 cell count, viral load, time since HIV diagnosis, history of AIDS‐defining illness and year of HAART initiation. In contrast, women had significantly higher risk of developing lactic acidosis than men (P = 0.0009). Hypersensitivity reactions were also more frequent in women than men (adjusted hazard ratio = 4.4 (95% CI: 2.1–9.3)). Collectively, these data suggest that metabolic toxicities after HAART do not differ by gender but that lactic acidosis and hypersensitivity reactions are more frequent in women than men. J. Med. Virol. 78:1158–1163, 2006.
- 1 April 2005
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 6 (2) , 63-72
Virologic and Immunologic Response to a Boosted Double-Protease Inhibitor-Based Therapy in Highly Pretreated HIV-1-Infected Patients
Purpose: To assess the virologic and immunologic response to a boosted doubleprotease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steadystate saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63%) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥ 6 lopinavir mutations [odds ratio (OR) 0.03; 95% CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95%CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95% CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.
- 1 April 2005
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 6 (2) , 63-72
Virologic and Immunologic Response to a Boosted Double-Protease Inhibitor-Based Therapy in Highly Pretreated HIV-1-Infected Patients
Purpose: To assess the virologic and immunologic response to a boosted doubleprotease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. Method: In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, lamivudine, and other nucleoside analogues were offered to highly pretreated patients who had advanced HIV-1 infection and who had failed at least 2 previous highly active antiretroviral therapy regimens including at least 1 nonnucleoside reverse transcriptase inhibitor. The relationship between baseline drug resistance and steadystate saquinavir serum levels and early (week 4) and sustained (week 48) virologic response was documented. Results: 35 advanced HIV-1 patients were enrolled. The boosted double-PI regimen was well tolerated. Twenty-two (63%) of the 35 patients had a > 0.8 log10 decrease in HIV viral load at week 4. After 48 weeks of follow-up, the 22 patients who remained on the study therapy had an average decrease in viral load of 1 log10 and had a median increase in CD4 cells of 60 cell/μL. Multiple logistic regression analysis indicated that genotypic resistance to both PIs and the week-3 trough concentrations of saquinavir were associated with virologic outcome at week 4. The presence of ≥ 6 lopinavir mutations [odds ratio (OR) 0.03; 95% CI 0.01 to 0.79] and the 48V mutation (OR 0.01; 95%CI <0.01 to 0.88) was independently associated with lower odds of achieving an early response, whereas a higher saquinavir concentration at week 3 (OR 8.36; 95% CI 1.28 to 54.70) was associated with greater odds of an early response. Conclusion: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy.